Andrew is ranked in Tier 1 for mid-market M&A by both Chambers UK and legal 500 directories as well as being listed as one of The Lawyer's Hot 100. Andrew's clients describe him as 'a strong negotiator and problem solver' as well as 'fast and pragmatic and able to understand our needs very well'.

He has particular expertise in the Life Sciences sector and is recognised within the legal directories as a 'very talented' corporate and commercial lawyer with a long-standing commitment to the biotechnology and pharmaceutical industries. Andrew has a wealth of expertise in Indian and Russian M&A, having acted on some of the largest multi-billion dollar transactions to have taken place in those jurisdictions.

Whilst at his previous firm, Andrew led the team on the contested public takeover of his long-standing client Lavendon Group plc, a transaction which garnered industry recognition at The Legal Business Awards.

Afficher le CV complet Masquer le CV complet

Actualités et publications récentes

Sciences de la vie et Santé

Advising Apollo Therapeutics on $145 million financing

21 juin 2021

par Andrew Edge et Chris Cowley

Cliquer ici pour en savoir plus
Criminalité d’entreprise et conformité

Corporate Compliance @ Tech Deals in Germany - The Compliance Guarantee

10 septembre 2021
Briefing

par plusieurs auteurs

Cliquer ici pour en savoir plus
Fusions et acquisitions d’entreprises et marchés financiers internationaux

Double joy for our pro bono team in the Czech Republic

Available in Czech

9 septembre 2021

par Erwin Hanslik, MRICS et Barbora Antalíková

Cliquer ici pour en savoir plus
Data protection and cyber security
Fusions et acquisitions d’entreprises et marchés financiers internationaux

Taylor Wessing a accompagné Rambus dans le cadre de son acquisition du groupe PLDA

8 septembre 2021

par plusieurs auteurs

Cliquer ici pour en savoir plus